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Salmonella enterica serovar Typhi (S. Typhi), the causative agent of typhoid fever, and S.
Paratyphi A and B, causative agents of paratyphoid fever, are major public health threats
throughout the world. Although two licensed typhoid vaccines are currently available, they
are only moderately protective and immunogenic necessitating the development of novel
vaccines. A major obstacle in the development of improved typhoid, as well as paratyphoid
vaccines is the lack of known immunological correlates of protection in humans. Consider-
able progress has been made in recent years in understanding the complex adaptive host
responses against S. Typhi. Although the induction of S. Typhi-specific antibodies (includ-
ing their functional properties) and memory B cells, as well as their cross-reactivity with
S. Paratyphi A and S. Paratyphi B has been shown, the role of humoral immunity in pro-
tection remains undefined. Cell mediated immunity (CMI) is likely to play a dominant role
in protection against enteric fever pathogens. Detailed measurements of CMI performed
in volunteers immunized with attenuated strains of S. Typhi have shown, among others,
the induction of lymphoproliferation, multifunctional type 1 cytokine production, and CD8+
cytotoxic T-cell responses. In addition to systemic responses, the local microenvironment
of the gut is likely to be of paramount importance in protection from these infections. In this
review, we will critically assess current knowledge regarding the role of CMI and humoral
immunity following natural S. Typhi and S. Paratyphi infections, experimental challenge,
and immunization in humans. We will also address recent advances regarding cross-talk
between the host’s gut microbiota and immunization with attenuated S.Typhi, mechanisms
of systemic immune responses, and the homing potential of S.Typhi-specific B- andT-cells
to the gut and other tissues.
Keywords: Salmonella Typhi, Salmonella Paratyphi, enteric fever, typhoid fever, human immunity, CMI,
multifunctionalT-cells, microbiota
INTRODUCTION
Enteric fevers encompass typhoid fever caused by the Gram-
negative intracellular bacterium Salmonella enterica serovar Typhi
(S. Typhi) and paratyphoid fever caused largely by S. enterica
serovars Paratyphi A and B (S. Paratyphi) (1, 2). Most cases
of enteric fever are caused by S. Typhi (3). However, infections
caused by S. Paratyphi A have been increasing in recent years,
particularly in Asia (2, 4–7). Typhoid and paratyphoid fevers are
life-threatening illnesses exhibiting very similar clinical features
(2, 8). Humans are the only reservoir for these infections. The
disease spreads by the fecal–oral route via contaminated food and
water (9). In industrialized countries, enteric fevers are rare with
most infections occurring in military personnel and in individuals
traveling to endemic areas. According to the CDC, in the United
States, it is estimated that ~5,700 cases of S. Typhi infection occur
annually, mostly acquired while individuals are traveling inter-
nationally. However, S. Typhi and S. Paratyphi infections are a
major public health problem in the developing world (9–13). It
is estimated that 26.9 million new cases of typhoid fever occur
annually with about 1% mortality (9–13). Based on data provided
by the World Health Organization, 90% of these typhoid deaths
occur in Asia, and most victims are children under 5 years of age
(14). Furthermore, antimicrobial treatment of enteric fever and
asymptomatic carriers has become increasingly complicated due
to the emergence of multidrug-resistant strains of S. Typhi and S.
Paratyphi A (7, 15, 16). Thus, there has been an increased emphasis
on control measures, such as improved sanitation, food hygiene,
and vaccination (8, 10, 17). It has also become evident that a bet-
ter understanding of the host immune responses against S. Typhi
and S. Paratyphi are required. This review will focus on the adap-
tive human immune responses [i.e., humoral and cell mediated
immunity (CMI)] to S. Typhi and S. Paratyphi acquired through
natural infection, experimental challenge, and vaccination. For
discussions of the “mouse model of Salmonella infection,” the
reader is referred to excellent reviews included in this “Frontiers
in Immunology Research Topic” compilation.
IMMUNITY ELICITED IN NATURAL INFECTIONS CAUSED BY
S. Typhi AND S. Paratyphi
Salmonella Typhi is a facultative intracellular bacterium that causes
an acute generalized infection of the reticuloendothelial system
(RES), intestinal lymphoid tissue, and gallbladder in humans
(18). Classical symptoms include gradual onset of sustained fever,
chills, hepatosplenomegaly, and abdominal pain. In some cases,
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patients experience rash, nausea, anorexia, diarrhea, or constipa-
tion, headache, relative bradycardia, and reduced level of con-
sciousness (19). After S. Typhi ingestion, the period of incubation
ranges from 3 to 21 days, with the mean incidence between 8 and
14 days (19). Without effective treatment, typhoid fever has a case-
fatality rate of 10–30%. This number can be reduced to 1–4% with
appropriate therapy (10). In addition, a small number of individ-
uals become “carriers.” These individuals, after recovering from
acute S. Typhi infection, keep shedding S. Typhi in their feces and
are able to spread the disease.
After ingestion of contaminated food or water, sufficient num-
bers of S. Typhi might survive the low pH of the stomach and
cross the intestinal epithelial monolayer through mechanisms that
involve M cells, dendritic cells (DC), passage through enterocytes
in endocytic vacuoles, and/or disruption of tight junctions (para-
cellular route) (20, 21). Once in the lamina propria, S. Typhi can
spread systemically and trigger innate and adaptive host immune
responses.
Most of our knowledge of adaptive host immune responses
to S. Typhi natural infection originates from studies involving
individuals living in typhoid endemic areas (21–23). Clinical stud-
ies indicate that the development of protective immunity after
recovery from typhoid fever is possible but that the frequency of
individuals able to mount protective immune responses is low
(22, 23). S. Typhi infections in individuals living in endemic areas
elicit the appearance of both humoral and CMI responses. Anti-
S. Typhi-specific antibodies against lipopolysaccharide (LPS), H
(flagellin), Vi (S. Typhi capsular polysaccharide; virulence fac-
tor), porins, and heat-shock proteins (e.g., GroEL), among others,
have been well documented in the sera of acute and convales-
cent typhoid fever patients (24–31). In addition, the presence of
anti-S. Typhi secretory IgA (SIgA) was also described in intestinal
fluids of typhoid patients (32). Of note, high-anti-Vi IgG anti-
bodies are present in a considerable proportion of chronic biliary
S. Typhi carriers, particularly in endemic areas. The presence of
functional antibodies against S. Typhi (e.g., bactericidal activity),
which increase with age has also been reported in healthy residents
of typhoid endemic areas (33). However, the role that antibodies
play in protection remains elusive. For example, susceptibility to
typhoid infection has been reported to occur despite the presence
of elevated titers of antibodies against O, H, and other S. Typhi
antigens (22, 23, 29, 34).
Clinical observations suggest that CMI, particularly cytokines,
play an important role in host defense against Salmonella infec-
tion. For example, increased susceptibility to invasive Salmonella
infections, caused largely by non-typhoidal Salmonella, as well as a
few S. Typhi and S. Paratyphi cases, have been reported in individ-
uals with immune deficiencies for interferon (IFN)-γ, interleukin
(IL)-12, IL-23, and STAT1 receptors (35–38). Moreover, signif-
icant genetic associations were reported between susceptibility
or resistance to typhoid fever and HLA-DR and HLA-DQ MHC
and tumor necrosis factor (TNF)-α alleles in Vietnam residents
(39). Of note, although the data is sparse, it has been reported
that human immunodeficiency virus (HIV) positive patients in an
endemic area are at significantly increased risk for infection with
S. Typhi and S. Paratyphi (40). However, these results will need
further confirmation as other studies have failed to observe this
association (36).
The importance of CMI in the host’s response to S. Typhi has
also been derived from early studies in acute and chronic car-
rier typhoid patients, which demonstrated the presence of specific
CMI responses, including antigen-specific lymphoproliferation,
leukocyte migration inhibition, and rosette-forming cells (32, 41–
46). Moreover, elevated serum levels of IFN-γ, IL-6, and TNF-α
receptor (TNF-R) p55 and TNF-R p75 were reported in S. Typhi
and S. Paratyphi A-infected patients in Nepal (47). Interestingly,
in these studies higher values of IL-6 and soluble TNF-R p55
were related to poorer outcome. In another study, Keuter et al.
showed that levels of the anti-inflammatory mediators IL-1 recep-
tor antagonist (IL-1RA), soluble TNF-R (p55 and p75), and IL-8
were higher in the acute phase than in the convalescent phase (48).
In contrast, the production capacity of pyrogenic cytokines (TNF,
IL-6) was depressed in the acute phase of typhoid fever but was
restored during the convalescent phase. Of note, no differences
were observed between patients with complicated or uncompli-
cated disease courses. These observations have been extended by
recent studies in Bangladeshi typhoid patients, which have shown
the induction of specific T-cell responses [e.g., production of
IFN-γ, IL-17, macrophage inflammatory protein (MIP)-1β, lym-
phoproliferation] to purified S. Typhi antigens using a novel high-
throughput technique (49–51). Concerning the cellular source
of cytokines/chemokines, experiments using human PBMC from
healthy subjects and Ty21a vaccinees have shown that, in addi-
tion to lymphocytes, stimulation with S. Typhi flagella induced
the rapid de novo synthesis of TNF-α and IL-1β, followed by IL-6
and IL-10 in macrophages (52). Follow-up experiments indicated
that whole-cell S. Typhi and S. Typhi flagella also have the ability to
downregulate in vitro lymphocyte proliferation to soluble antigens
and mitogens by affecting macrophage function, suggesting that S.
Typhi components have the potential to exert both up-regulatory
and down-regulatory effects on the host immune response (53).
Taken together, these observations suggest that although antibod-
ies are likely to participate in protection against typhoid fever, CMI
probably represent the dominant protective immune responses
that eventually lead to the elimination of these bacteria from the
host.
More limited information is available regarding immunolog-
ical responses in paratyphoid fever. Several reports showed the
presence of serological responses against LPS and H-flagellar
S. Paratyphi antigens using the Widal, colorimetric, and ELISA
tests (7, 54). More recently, immunogenic S. Paratyphi A pro-
teins expressed in bacteremic S. Paratyphi A-infected individuals
have been identified using an immunoscreening technique (IVIAT;
in vivo-induced antigen technology) (4). These studies identified
several S. Paratyphi A proteins expressed in vivo (~20 proteins,
including those involved in pathogenesis, such as fimbria, cell
envelope and membrane structures, energy metabolism, and cellu-
lar proteases), which elicited antibody responses in these patients
during the acute and convalescent phases. These results confirmed
and extended previous studies by the same group using a different
technique (SCOTS, selective capture of transcribed sequences) in
Bangladeshi patients who were bacteremic with S. Paratyphi A and
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S. Typhi (51, 55). Taken together, these observations highlight sev-
eral S. Paratyphi A proteins, which might play an important role
in S. Paratyphi A pathogenesis and which may serve as targets of
upcoming vaccine development efforts.
Regarding CMI, as reported in typhoid fever, elevated serum
levels of IFN-γ, IL-6, TNF-R p55, and TNF-R p75 were reported
in S. Paratyphi A-infected patients (47). Moreover, a very recent
manuscript described the induction of serum pro-inflammatory
cytokines in Israeli travelers who became infected with S. Paraty-
phi A while visiting Nepal (6). These studies showed elevated
serum levels of both pro-inflammatory and anti-inflammatory
cytokines/chemokines during the acute phase, including IFN-γ,
IL-6, IL-8, IL-10, IL-15, and TNF-α. Of note, no changes were
observed in the serum levels of the other cytokines evaluated in
these studies (i.e., IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-12p70, IL-13,
IL-17, IL-23, and TNF-β). These increases in pro-inflammatory
cytokines/chemokines observed in S. Paratyphi A infections are
similar to those reported in typhoid fever, supporting the con-
tention that similar host immune responses might be elicited in
enteric fevers caused by S. Typhi and S. Paratyphi bacteria. Inter-
estingly, elevated serum levels of pro-inflammatory (IFN-γ, IL-12,
and TNF-α) cytokines but decreased levels of IL-10 were reported
in patients with early non-typhoidal gastroenteric Salmonella bac-
terial clearance in stools as compared to the non-clearance group
(56). It is reasonable to speculate that these observations demon-
strating the increased circulating levels of both pro-inflammatory
and anti-inflammatory cytokines/chemokines suggest the con-
comitant presence of both T effector (Teff) and T regulatory (Treg)
responses following wild-type infection.
Another issue to consider regarding the cytokine/chemokine
data in natural infections with typhoidal and non-typhoidal
Salmonella is that although increases in circulating cytokines/
chemokines are widely considered to be associated with protective
responses, this might not necessarily be an accurate interpreta-
tion. In fact, it is likely that the levels of cytokines/chemokines in
the microenvironments of the gut and the “RES” (e.g., regional
lymph nodes, spleen, and other secondary lymphoid tissues) are
not necessarily reflected in circulation. These are the sites in which
most immune responses are likely to be generated, and where Sal-
monella find their niche(s) for long-term persistence, representing
important sites for localized immune responses. With the infor-
mation currently available, it is not possible to rule out the notion
that serum/plasma levels might be a representation of a general-
ized pro-inflammatory response (part of the so called “cytokine
storm,” a surrogate marker of inflammation) in response to a sys-
temic bacterial infection (e.g., the host’s response to LPS and other
bacterial antigens) rather than an effective targeted host response
leading to protection.
IMMUNITY ELICITED BY EXPERIMENTAL CHALLENGE WITH
WILD-TYPE S. Typhi (CONTROLLED HUMAN INFECTION
MODEL; TYPHOID CHI)
S. Typhi is a human-restricted pathogen, i.e., there are no good
animal models that faithfully recapitulate S. Typhi infection (57).
To partially address this shortcoming, the infection of suscepti-
ble mice with S. Typhimurium has been used as a model for
the pathogenesis of human typhoid fever (57). Although these
murine models have provided considerable knowledge regard-
ing host–pathogen interactions, they do not fully represent S.
Typhi infection in humans (58). Furthermore, the recent avail-
ability of full genome sequences from various S. enterica serovars
have uncovered many differences in inactivated or disrupted genes,
which can explain, at least in part, the dissimilarities observed in
the immune and other host responses to these enteric bacteria
(58). Thus, controlled human infection (CHI,“challenge”) studies
in which subjects are exposed orally to wild-type S. Typhi, have the
potential to provide a better understanding of the human immune
response to infection. Additionally, these studies have the capac-
ity to uncover the correlates of protection against S. Typhi, which
might prove critical to accelerate the development of better and
more effective vaccines to prevent typhoid and other enteric fevers
(59, 60).
While challenge experiments with virulent S. Typhi were
reported early in the twentieth century (59), University of Mary-
land Researcher, Dr. Theodore E. Woodward, is considered the
pioneer in the establishment of a reproducible challenge model
(61). In this challenge model, participants were orally challenged
with wild-type S. Typhi suspended in milk, without buffer. In his
first challenge assay performed in the 1950s, Dr. Woodward used
the wild-type strain Ty2 isolated from an outbreak in Kherson
(in modern day Ukraine) in 1918 (62). All subsequent challenge
assays were performed using the Quailes strain, which was isolated
from the gallbladder of a chronic carrier, and demonstrated vir-
ulence through transmission to several household members (60).
To highlight the importance of this challenge model, studies by
Dr. Woodward and his collaborators at the University of Mary-
land led to the successful use of chloramphenicol in the treatment
of patients with typhoid fever (61) and also served as the first step
toward eventual licensure of the Ty21a typhoid vaccine (63).
Very recently, over three decades after the last human wild-type
S. Typhi challenge study was performed at University of Mary-
land, Dr. Pollard’s group in Oxford (UK) has re-established this
model. This CHI model followed in the steps of previous stud-
ies by challenging healthy adult subjects with wild-type S. Typhi
Quailes strain (63). However, the challenge agent was suspended
in a sodium bicarbonate solution rather than milk. Two dose lev-
els (103 or 104 colony-forming units) resulted in attack rates of
55 or 65%, respectively. Interestingly, participants who developed
typhoid infection demonstrated serological responses to flagellin
and LPS antigens by day 14, while no changes were observed in
the titers of these antibodies in participants not succumbing to
infection after challenge. It is reasonable to speculate that the
increased anti-LPS responses in subjects who developed typhoid
was largely the result of clinical disease involving local and sys-
temic infection rather than representing a protective mechanism
at play. Moreover, anti-S. Typhi antibody baseline titers did not
correlate with subsequent infection risk (63). These results are
somewhat different than those from Maryland challenges in which
anti-H antibodies appear to correlate with protection. Of note, in
the Oxford CHI studies, antibody responses were not detected
against Vi, which is present in most S. Typhi isolates, including the
Quailes strain. These results are in agreement with the Maryland
challenge studies, which showed considerable increases in flagellin
and LPS antibody titers soon after infection (during the incubation
www.frontiersin.org October 2014 | Volume 5 | Article 516 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sztein et al. Adaptive immunity to enteric fevers
period) but only modest rises in anti-Vi antibody titers (64). Of
note, clinical illness and relapse were reported in the Maryland
challenge studies to occur at the peak of antibody responses (64).
Taken in concert, these results suggest that anti-Vi and other anti-
S. Typhi-specific antibodies are likely to play a role in protection
during natural infection. However, their precise contribution to
host defense, either independently or in conjunction with other
effector immune responses, remains to be established.
The Maryland CHI studies conducted in the 1950s, 1960s, and
1970s did not address the role of CMI in protection against S.
Typhi infection, primarily due to the lack of appropriate assays. It is
likely, however, that the performance of in depth CMI studies with
specimens obtained from subjects participating in the recently re-
established Oxford typhoid CHI model using the most advanced
current techniques and instrumentation, will greatly advance our
understanding of the role of CMI in protection.
TYPHOID AND PARATYPHOID VACCINES: CURRENT STATUS
The first typhoid vaccines consisting of inactivated (heat-killed,
phenol-preserved) S. Typhi delivered parenterally were developed
as far back as 1896 by Pfeiffer and Kolle in Germany and Wright
in England (65). At that time, typhoid fever was a much-feared
disease. However, following the discovery that antibiotics such as
chloramphenicol could successfully treat typhoid fever, the inter-
est in typhoid vaccines waned. A resurgence of interest in typhoid
vaccines began in the 1970s, when epidemics of chloramphenicol-
resistant typhoid occurred in Mexico and Vietnam (1). Although
inactivated whole-cell vaccines are immunogenic and effective,
due to excessive reactogenicity, they are no longer manufactured
(66–68). Currently, there are two vaccines against S. Typhi that are
licensed in the USA for use in humans, the purifiedVi (“virulence”)
polysaccharide parenteral vaccine and the oral live-attenuated S.
Typhi strain Ty21a vaccine. Both vaccines are moderately protec-
tive and have been shown to induce herd immunity (69, 70). The
Vi polysaccharide vaccine was developed by Robbins and collab-
orators at NIH as an injectable subunit vaccine and is currently
sold by several companies, including Sanofi Pasteur and Glaxo-
SmithKline (Table 1) (69, 71–75). Although the Vi vaccine confers
a moderate level (55–72%) of protection in children over 2 years
of age after a single dose, this vaccine does not confer “mem-
ory” and there are no robust data to suggest that the efficacy
of Vi persists beyond 3 years (66, 67, 69, 76). The Ty21a vac-
cine, licensed for children older than 6 years, confers a moderate
level of long-lived protection (60–80%, 5–7 years) but requires
the administration of three to four spaced doses (66, 70, 77).
Despite its moderate immunogenicity much of our knowledge
regarding immunological responses against S. Typhi has been
derived from studies of Ty21a immunization (Table 1) (52, 66,
67, 78–92). Vaccination of children younger than 2 years old, how-
ever, requires a new approach. The Vi-protein-conjugate vaccines
appear promising in this regard (14, 93–96). Conjugate Vi vaccines
consist of the S. Typhi Vi polysaccharide, a T-cell-independent
antigen, covalently bound to a carrier protein. Hence, the con-
jugation process increases the immunogenicity of the vaccine
by converting the Vi polysaccharide into a “T-cell-dependent”
antigen. Various Vi-conjugate vaccine candidates are in develop-
ment. For example, Vi O-Acetyl Pectin-rEPA conjugate vaccine,
a modified conjugate vaccine where Vi is conjugated to non-
toxic recombinant Pseudomonas aeruginosa exotoxin A (rEPA) has
shown an efficacy of ~90% in 2–5-year-old children (94, 96–99).
Recently, Bharat Biotech in India has launched the world’s first Vi-
conjugate vaccine, called Typbar-TCV™, consisting of Vi from S.
Typhi strain Ty2 conjugated to tetanus toxoid (TT) as a carrier pro-
tein, which can be given to infants older than 6 months (100, 101).
Other vaccine candidates include Vi-conjugated to CRM197 (95)
and diphtheria toxoid (102) (Table 1). Of note, issues that have
been raised and merit consideration regarding the use of Vi and
Vi-conjugate vaccines are the emergence of S. Typhi Vi antigen-
negative strains in multidrug-resistant typhoid fever cases and the
possibility that the generalized use of Vi vaccines might lead to
increased incidence of enteric fevers caused by Vi-negative strains
for which Vi vaccines will be ineffective (103, 104). As a result of
these issues, as well as other scientific, logistical, and economic
reasons, additional subunit vaccine candidates are being actively
developed for the prevention of enteric fevers. These include,
among others, conjugates of S. Typhi and S. Paratyphi A LPS
to carrier proteins or Salmonella proteins (e.g., flagellin, porins)
to extend the generation of immunity to other relevant specific
antigens (101).
Because of the above considerations, investigators, including
those at the University of Maryland Center for Vaccine Devel-
opment (CVD), have engineered new attenuated typhoid vaccine
strains that aim to be as safe as Ty21a but immunogenic and pro-
tective following the ingestion of only a single dose. These vaccine
candidates include Ty800 (113), M01ZH09 (114–120), and others
based on attenuation of S. Typhi by deletions of genes such as those
involved in the synthesis of aromatic amino acids (aroC, aroD) and
heat-shock proteins (htrA). The latter vaccine candidates, desig-
nated CVD 906 (105, 106), CVD 908 (107–109), CVD 908-htrA
(110), and CVD 909 (112), have been evaluated in volunteers and
shown to induce potent CMI both in vitro and ex vivo (83–85,
105, 107, 110–112, 121–123), as well as humoral responses (105,
108, 110, 112) (see below for details). Except for CVD 906, these
strains are derived from the wild-type S. Typhi Ty2 strain, the same
strain from which the Ty21a vaccine was derived. Table 1 includes
a summary of the characteristics of these typhoid vaccine strains
and the documented immune responses elicited in volunteers.
Regarding S. Paratyphi vaccines, the first killed whole-cell par-
enteral typhoid vaccines produced a century ago consisted of a
trivalent combination of heat-inactivated and phenol-preserved
S. Typhi, S. Paratyphi A, and S. Paratyphi B (TAB vaccine) (67).
Although this vaccine was moderately efficacious, its manufacture
was discontinued due to high levels of reactogenicity (2). Although
several vaccine candidates against enteric fever caused by S. Paraty-
phi A are at various stages of development, including S. Paratyphi A
O-specific polysaccharide-TT and CRM197 conjugates (124–126),
no vaccines are currently commercially available.
It is important to note that there has been considerable interest
in exploring the use of attenuated S. Typhi strains as live-vector
vaccines. S. Typhi presents multiple advantages as a live-vector,
including (a) oral delivery, (b) targeting of M cells overlying gut-
associated lymphoid tissue (inductive sites for immune responses),
(c) internalization by DC and macrophages, and (d) stimula-
tion of broad immune responses (127). Indeed, multiple clinical
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Table 1 | Selected licensed S.Typhi vaccines and vaccine candidates.
Type of
vaccine
Trade name Licensed Manufacturer/
developer
Number of
doses
Efficacy
(field trials)
Minimum age for
administration
Immunogenicity data Reference
Inactivated
whole cell
N/A Yes No longer being
manufactured
2 ~60–80% N/A Serum antibodies, lymphocyte proliferation, PBMC
migration inhibition
(66–68)
Live
attenuated
Ty21a (Vivotif ®) Yes Crucell Switzerland Ltd 3–4 ~60–80% ≥6 years Serum antibodies, ASC, ALS, ADCC,
opsonophagocytosis, B memory, lymphocyte
proliferation, production of multiple cytokines, and
chemokines, CTL activity, cross-reactivity with S.
Paratyphi A & B
(52, 66, 67,
78–92)
CVD 906 No CVD–UMB 1 N/A N/A Serum antibodies, jejunal IgA, ASC, lymphocyte
proliferation, IFN-γ and IL-6 production
(105–107)
CVD 908 No CVD–UMB 1 N/A N/A IgA ASC, serum IgG, lymphocyte proliferation,
IFN-γ and IL-6 production
(107–109)
CVD 906-htrA No CVD–UMB 1 N/A N/A Serum antibodies, jejunal IgA, ASC, lymphocyte
proliferation
(110)
CVD 908-htrA No CVD–UMB 1 N/A N/A Serum antibodies, jejunal IgA, ASC, lymphocyte
proliferation, IFN-γ production
(110, 111)
CVD 909 No CVD–UMB 1 N/A N/A Serum antibodies, ASC, ALS, B memory,
opsonophagocytosis, lymphocyte proliferation,
cross-reactivity against S. Paratyphi A and B
(89, 90, 112)
Ty800 No Massachusetts General
Hospital
1 N/A N/A IgA ASC, serum IgG and IgA (113)
M01ZH09 No Microscience Limited 1 N/A N/A Serum antibodies, ASC, ALS, opsonophagocytosis,
bactericidal, lymphocyte proliferation, IFN-γ
production
(114–118)
χ3927 No CVD–UMB 1 N/A N/A Serum antibodies, Jejunal sIgA, ASC (105)
SUBUNIT
Vi
polysaccharide
Typhim Vi® Yes Sanofi Pasteur 1 55–72% ≥2 years Serum antibodies (66, 67, 72)
Typherix ® Yes GlaxoSmithKline 1 61% ≥2 years Serum antibodies (66, 67, 69)
Typbar® Yes Bharat Biotech 1 N/A ≥2 years Serum antibodies (73)
Vax-TyVi® Yes Finlay Instituto 1 N/A ≥5 years Serum antibodies (74)
TyViVac Yes Dalat Vaccine Company
(DAVAC)
1 N/A ≥2 years Serum antibodies Product insert
BioTyphTM Yes BioMed 1 N/A ≥2 years Serum antibodies Product insert
(Continued)
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trials have been performed to investigate the immunogenicity of
genetically engineered S. Typhi expressing foreign antigens (111,
127–134). While these studies have detected only modest immune
responses against the foreign antigens, novel engineering strate-
gies hold great potential to enhance the immunogenicity of such
vaccines (127). This remains an important avenue of research and
improved understanding of immune responses elicited by S. Typhi
and S. Paratyphi A vaccines may facilitate these efforts.
ADAPTIVE RESPONSES TO S. Typhi IN VOLUNTEERS
IMMUNIZED WITH LICENSED TYPHOID VACCINES AND
VACCINE CANDIDATES
As discussed above, immunity to S. Typhi is complex involving
antibodies and CMI (135–138). Because S. Typhi is a facultative
intracellular bacterium, we and others have hypothesized that both
antibodies and CMI might play complementary roles in protection
from infection. While antibodies are likely to play an important
role in defense against extracellular bacteria, CMI is expected to
be essential in eliminating S. Typhi-infected cells. Based on results
from studies using specimens from subjects immunized with
attenuated typhoid vaccines, we surmise that serum antibodies,
SIgA, CD4+, CD8+, and other T-cell subsets (e.g., mucosal associ-
ated invariant T-cells, MAIT), as well as the interaction between T,
B, and antigen-presenting cells (APC, e.g., macrophages, DC) are
all likely to contribute to an effective acquired immune response
against typhoid fever (Figure 1). However, the relative contri-
bution of each main arm of the effector immune response, i.e.,
humoral and cellular, and the antigen specificity of the responses
remain largely unknown. Below, we will critically address the key
humoral and CMI responses, which we believe are essential in gen-
erating “protective” immunity against S. Typhi infection, as well as
discuss current gaps in knowledge, which need to be addressed to
enable the identification of immunological correlates of protection
in enteric fevers.
HUMORAL RESPONSES
Antibodies
Numerous studies have reported serum antibody production fol-
lowing S. Typhi infection and immunization. Antibodies against
the O antigen of S. Typhi LPS, the Vi antigen, and the H antigen
are routinely measured as markers of immunogenicity follow-
ing S. Typhi immunization (67, 110, 112–114, 139, 140). Despite
extensive study, the precise role that antibodies play in protection
against S. Typhi remains unknown. As discussed above, relapses of
typhoid fever occur in individuals despite elevated titers of serum
anti-S. Typhi antibodies (34, 141) and in a recent human chal-
lenge with wild-type S. Typhi, pre-challenge levels of anti-H and
Vi antibodies did not correlate with protection (63). These studies
showed that volunteers who were diagnosed with typhoid demon-
strated increases in IgG, IgM, and IgA to LPS and H antigens
while little change was seen in volunteers who did not succumb
to the disease (63). Anti-Vi levels remained unchanged through-
out the study (63). Nevertheless, the fact that Vi polysaccharide
vaccines can induce protection against typhoid indicates that high-
anti-Vi antibodies are protective. In fact, defined levels of serum
anti-Vi antibodies (1.4–2.0µg/ml) have been reported to act as a
serological surrogate of protection in Vi-rEPA conjugate vaccine
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FIGURE 1 | Simplified diagram of immunity to S.Typhi in humans.
Immunity to S. Typhi is extremely complex involving multiple
antigen-presenting cells (e.g., macrophages, dendritic cells, B cells) and
effector cells (e.g., various effector and regulatory T-cell subsets, B cells, NK,
and MAIT cells). APC, antigen-presenting cells; ASC, antibody secreting cells;
DC, dendritic cells; CD8, CD8+ T-cells; CD4, CD4+ T-cells; MAIT, mucosal
associated invariant T-cells; Mϕ, macrophages; NK, natural killer cells; PMN,
polymorphonuclear neutrophil; TM, memory T-cells; TCM, central memory
T-cells; TEM, effector memory T-cells; TEMRA, effector memory expressing
CD45RA; Treg, regulatory T-cells; HLA, human leukocytes antigen; HLA-I, HLA
class I; HLA-II, HLA class II; BCR, B cell receptor; TCR, T-cell receptor; MR1,
HLA-I non-classical (b) molecule MR1; Ig, immunoglobulin.
efficacy trials (94). Presumably, anti-Vi antibodies function by
counteracting the evasion of innate immune recognition in the
intestinal mucosa and obstruction of bacterial-guided neutrophil
chemotaxis, which have been proposed as possible mechanisms
by which Vi subverts host immune responses (142, 143). Inter-
estingly, the live-attenuated oral vaccine Ty21a, which lacks the
Vi antigen, results in similar levels of protection as those of the
Vi polysaccharide vaccine (12), indicating that multiple adap-
tive immunological responses can lead to effective protection
(Table 1). In field studies of an enteric-coated capsule formu-
lation of Ty21a, seroconversion, as measured by anti-O IgG,
correlated with protection (67, 144). However, in these same clin-
ical trials the seroconversion rate of IgG O antibodies did not
predict the poor efficacy of other vaccine formulations (67). Sero-
conversion against S. Typhi-O antigen has, nevertheless, been
used as a marker of immunogenicity following immunization
with single-dose live-attenuated vaccine candidates (110, 112–114,
140). In addition to serum antibodies, S. Typhi-specific IgA can
be found in saliva, intestinal fluids, and stools following oral
immunization with live-attenuated S. Typhi or natural infection
(26, 78, 145, 146).
Immunoglobulins can be divided into subclasses (e.g., IgA1 and
IgA2) based on structural, antigenic, and functional differences
(147). The subclasses of IgA are not evenly distributed among
bodily fluids with IgA1 dominating in serum and IgA2 found
primarily in secretions. In individuals immunized with Ty21a vac-
cine, S. Typhi-specific IgA1 predominated in serum, saliva, and
tears, while IgA2 predominated in intestinal lavage fluid (146).
IgG can be subclassified into IgG1-4 with different subclasses typ-
ically responding to different types of antigen. For example, IgG1
and IgG3 are generally induced by protein antigens, while IgG2
and IgG4 antibodies are associated with polysaccharide antigens
(147). Interestingly, however, serum antibodies against Salmo-
nella LPS belong primarily to the IgG1, IgA1, and IgA2 subclasses
(148). In contrast, as expected, IgG2 anti-Vi was found to be the
predominant IgG subclass in a Vi polysaccharide vaccine study
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in Nepal (33). Moreover, following a single subcutaneous dose
of an S. Typhi vaccine candidate containing porins (protein anti-
gen) IgM and both IgG1 and IgG2 seroconversions were detected
(136). Unfortunately, no information is available on the avidity of
anti-S. Typhi antibodies elicited by natural infection or immuniza-
tion. This is a key measurement of the strength of the attachment
of antibodies to their antigen, which is highest after B cells have
been adequately primed and is an important measurement of the
strength of the anamnestic response. Further understanding of the
specific immunoglobulin subclasses and avidity associated with
protective responses will be of importance in informing decisions
regarding vaccine development.
Despite the large amounts of data regarding production of anti-
bodies against S. Typhi, there have been few investigations of the
functional properties of these antibodies. Early studies indicated
that S. Typhi-specific IgA was responsible for antibody depen-
dent cellular cytotoxicity (ADCC) following Ty21a immunization
(87). In Nepal, an S. Typhi endemic region, bactericidal activity
of serum was shown to increase with age; however, no correla-
tion was found between bactericidal titer and anti-Vi titers (33).
Recently, we, and others, have reported the induction of func-
tional opsonophagocytic bactericidal S. Typhi-specific antibodies
that might assist in the elimination of S. Typhi (90, 118). These
opsonophagocytic antibodies appear to be of the IgG isotype.
Further investigation of these functional antibodies may lead to
improved measures of immunogenicity and might prove to be
more closely associated with protective immunity than antibody
measurements by ELISA.
In sum, the sometimes conflicting and fragmentary data
regarding the role of antibodies in defense against S. Typhi sug-
gest that while they may contribute to an effective response, they
are unlikely to represent the dominant mediator of protection in
humans following exposure to wild-type organisms.
B cells
Although, studies in knockout mice indicate that B cells play an
important role in protection against S. Typhimurium (149), the
precise role that B cells play in protection against S. Typhi in
humans remains unknown. Antibody production is clearly a major
function of B cells; however, B cells also contribute to immune
responses via antigen presentation, cytokine production, and the
initiation of T-cell responses. For example, Salmonella-specific
primary human B cells are able to internalize S. Typhimurium
via their B cell receptor and stimulate a strong recall response by
cytotoxic CD8+ T-cells (150). In fact, following internalization,
Salmonella survive in the B cell and antigens are loaded onto MHC
class I for cross-presentation to CD8+ T-cells (150). These results
are supported by our previous observations showing that S. Typhi-
infected B cells can serve as excellent APC for S. Typhi antigens. We
reported that Epstein–Barr virus (EBV)-transformed lymphoblas-
toid B cell lines (B-LCL) are able to effectively stimulate CD4+
cells as well as classical and non-classical CD8+ cells (82–85, 92,
121–123, 151, 152). These findings also re-emphasize the impor-
tance of communication among immune cell compartments and
the possibility that B cells contribute to host defense from S.
Typhi infection through mechanisms beyond their primary role
in antibody production (20) (Figure 1).
Antibody secreting cells. A key aspect of B cells is their abil-
ity to undergo cell differentiation and become antibody secreting
cells (ASC) (153). In Salmonella infection, specific ASC circulate
briefly systemically, peaking at ~7–10 days after antigen encounter,
before homing to mucosal effector sites (91, 110, 112, 113, 115, 140,
144, 154–157). However, prolonged exposure to antigen results in
extended circulation of S. Typhi-specific ASC in peripheral blood
(158). In fact, patients with prolonged diarrhea have circulating
ASC throughout the duration of the pathogen exposure (158).
Following mucosal antigen encounter (i.e., oral immunization),
S. Typhi-specific IgA ASC predominate followed by substantial
IgM ASC and low numbers of IgG ASC (79, 158). Of note, the
magnitude of ASC response displays considerable inter-individual
variation. Three main factors appear to dictate the magnitude of
the response: antigen type (live versus killed), number of vaccine
doses ingested, and formulation of the vaccine (158). Specifi-
cally, immunization with a live oral vaccine resulted in higher
magnitude of ASC responses compared to a killed vaccine (159).
Ingestion of three doses of vaccine resulted in higher numbers
of S. Typhi-specific ASC than did two doses and, although there
was no further increase in the peak number of ASC following six
doses, the response remained higher for a longer duration (158).
Additionally, different vaccine formulations (i.e., gelatin capsules,
enteric-coated capsules, suspension) showed different magnitudes
of response, with the suspension-formulation, resulting in the
highest number of S. Typhi-specific ASC (79, 158). Notably, the
magnitude of the IgA ASC response against the O antigen induced
by different formulations and schedules of Ty21a correlated with
the efficacy shown in field trials of the same formulations and
schedules (79, 144). Other studies showed that the serum anti-
body increased concomitantly with increasing ASC numbers, and
that, when ASC numbers were low, serum antibody responses were
undetectable (79). Consequently, it has been proposed that detec-
tion of ASC is a more sensitive measurement of immunogenicity
than serum antibody titers. The homing patterns of S. Typhi-
specific ASC have been rigorously studied and are discussed in
detail below.
Memory B cells. It is widely accepted that immunological mem-
ory is of critical importance for the development of long-lasting
protective responses following immunization (160). Memory B
cells (BM) are long-lived antigen primed cells that upon antigenic
stimulation during a secondary response undergo rapid terminal
differentiation into plasmablasts and plasma cells (161). While
there are multiple classification methods to define this hetero-
geneous population, most BM are widely accepted to exhibit the
phenotype CD19+ CD27+ IgD+/−, although a minor BM subset
lacking CD27 expression has also been reported (162). Of note,
it has been reported that BM are able to mature either inside or
outside of the germinal centers and that this phenomenon may
be T-cell-dependent or independent (161, 163). We have recently
made the novel observation that immunization with attenuated
S. Typhi vaccines elicits CD19+ CD27+ BM specific for S. Typhi
antigens (e.g., LPS, flagella, Vi) (89) and described the longevity
(up to 1 year), magnitude, and characteristics of these responses
(89). Notably, strong BM responses against both T-cell-dependent
(flagella) and T-cell-independent (LPS and Vi) antigens were
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identified in volunteers primed with CVD 909 (aVi expressing live-
attenuated S. Typhi vaccine candidate). These results suggest that
immunization with CVD 909 was capable of mucosally priming
the immune system to deliver robust and sustained Vi-specific BM
responses to a subsequent parenteral exposure. LPS-specific BM
responses were also observed in volunteers primed with CVD 909,
but these responses were of lower magnitude than those against
Vi. Similar to findings for ASC, LPS-specific IgA BM cells predom-
inated over LPS-specific IgG BM responses. In the same study, we
observed that volunteers immunized with Ty21a also developed
IgA BM responses to LPS, but only a single volunteer developed
IgG BM responses against LPS. Moreover, both CVD 909 and Ty21a
were capable of inducing anti-S. Typhi flagella IgG and IgA BM
responses. Finally, we observed a strong association between the
frequency of antigen-specific BM cells and antibody levels, sup-
porting an important role of this cell population in the generation
of humoral responses. Recent studies have shown that S. Typhi
porins can induce short- and long-lasting IgG and IgM responses
in humans, a response likely to be mediated by BM (136). Interest-
ingly, studies in mice have also identified IgM BM, which are likely
to secure long-term production of bactericidal IgM antibodies
following inoculation with S. Typhi porins (164). This study also
reported the induction of Type 1 T follicular helper (Tfh) cells that
produce IFN-γ, which are thought to support the generation of
these BM (164). However, the relative contribution of the various
BM and Tfh subsets to enduring protection remains to be deter-
mined. Further characterization of these responses and cell subsets
may help elucidate mechanisms of sustained protection against S.
Typhi.
B cell phosphorylation. Early signaling events that occur fol-
lowing encounter of B cells with S. Typhi and other pathogens
are of critical importance in the generation of cellular responses.
Recently, we described the phosphorylation patterns associated
with S. Typhi-specific B cells (165). We reported that exposure of
PBMC from healthy volunteers to fluorescently labeled, heat-killed
S. Typhi resulted in bacterial binding to naïve and unswitched
memory (Um) B cells as detected by flow cytometry. Although
naïve B cells that interacted with S. Typhi were observed, phos-
phorylation of Stk, Akt, and p38MAPK were not identified in this
subset. In contrast, Um B cells showed multi-phosphorylation of
all three proteins assayed, as well as cells that phosphorylated only
p38MAPK or Akt and p38MAPK. Interestingly, different antigenic
structures appeared to induce different patterns of phosphory-
lation. For example, the phosphorylation patterns induced by
S. Typhi were dramatically different from the phosphorylation
patterns induced by the Gram-positive bacterium Streptococcus
pneumoniae. These novel studies provide the first glimpse of
the activation pathways of S. Typhi-specific B cell responses in
humans. Further characterization of these mechanisms can pro-
vide key information to help advance the generation of novel
vaccine strategies.
B cell homing. Although most of our knowledge of immune
responses against Salmonella in humans is derived from studies
using peripheral blood, effector immunity in the local microen-
vironment of the gut is likely to be of paramount importance
in the understanding of protection against S. Typhi infection.
Mucosal derived circulating IgA ASC detected after administra-
tion of live oral typhoid vaccines have been used to estimate the
degree of priming of the local intestinal immune system (137).
These cells are believed to home to the lamina propria of the
intestinal mucosa where they will synthesize and release antibod-
ies (166). Selective homing of cells (including plasmablasts) to the
small intestine is believed to be largely driven by the expression
of integrin α4β7 and chemokine (C–C motif) receptor (CCR)9
(167), while CCR10 expression appears to be involved in homing
to “common” mucosal tissues (168). The primary site of antigen
encounter has been shown to affect the expression of homing
receptors on ASC (169). Following mucosal antigen delivery by
Ty21a administration, robust migration of S. Typhi-specific IgM
and IgA ASC toward chemokine (C–C motif) ligand (CCL)25
and CCL28, the ligands for CCR9 and CCR10, respectively, were
noted (170). In contrast, systemically derived tetanus-specific ASC
did not migrate toward either CCL25 or CCL28, supporting the
mucosal specificity of these ligands. Previous work has shown that
after oral antigen administration, the majority of ASC produce the
mucosal Ig-isotype, IgA, and all of them express the gut homing
receptor, integrin α4β7, thus, implying mucosal homing of these
cells (137, 154, 157, 158). Moreover, when comparing oral Ty21a
and parenteral Vi-conjugate vaccines, Ty21a but not Vi immuniza-
tion recapitulates the homing receptor profile of ASC occurring
in natural infection (e.g., integrin α4β7 expression) (155). We
have recently shown that sorted IgG and IgA ASC recognizing
S. Typhi-LPS are predominantly CD19+ CD27+ (a phenotype
associated with BM and plasmablasts) with selective gut homing
potential (e.g., integrin α4β7+ CD62L−) (91). Of note, however,
both IgG and IgA cells were also observed among integrin α4β7+
CD62L+, suggesting that they have the capacity to home to the
gut, as well as peripheral lymph nodes, and perhaps other sec-
ondary lymphoid tissues. Further studies of the homing potential
of S. Typhi-specific BM and plasmablasts is of critical importance
to further our understanding of the mechanisms underlying the
induction of antigen-specific cells which have the ability to home
to the gut (the initial site of infection), as well as to other lymphoid
tissues where S. Typhi resides following systemic dissemination.
CELL MEDIATED IMMUNE RESPONSES
As for other intracellular infections, CMI responses against S.
Typhi infection rely largely on two types of cells: CD4+ and CD8+
T-cells (51, 81, 138, 171). The presence of both CD4+ helper T-
cells and classical class Ia and non-classical HLA-E-restricted S.
Typhi-specific CD8+ T-cells have been observed in individuals
with typhoid fever or immunized with Ty21a and other attenu-
ated leading typhoid vaccine candidates, including CVD 908-htrA
and CVD 909 (51, 82–85, 88, 92, 114, 122, 123, 152, 172). A succinct
description of these responses follows.
T-cell responses
We, and others, have reported that S. Typhi can stimulate the
production of an array of pro-inflammatory cytokines including
IFN-γ by specific CD4+ and CD8+ T-cells following immuniza-
tion (52, 84, 85, 88, 107, 114, 121). For example, IFN-γ production
by CD4+ and CD8+ T-cells in response to S. Typhi LPS and flagella
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antigens has been shown up to 56 days after immunization with
attenuated S. Typhi vaccines (84, 107, 121). Similarly, in subjects
immunized with Ty21a, it has been shown that S. Typhi GroEL trig-
gers IFN-γ production by CD8+ cells (85). In addition, S. Typhi
immunization elicits the generation of cytotoxic CD8+ T-cells
(84, 121, 122). Cytotoxic CD8+ T-cells induce apoptosis within
minutes of contact with their target by at least two lytic mech-
anisms (173–175). One, based on granular exocytosis involving
perforin and granzymes (176), and another involving a mole-
cule called FAS or APO-1 (177). Using PBMC from individuals
immunized with the Ty21a typhoid vaccine (85) and the vaccine
candidate strain CVD 909 (123), we have shown that the killing
of S. Typhi-infected targets by specific CD8+ T-cells is largely
through a FAS-independent, granule-dependent pathway. These
findings were confirmed using two types of autologous target cells:
phytohemagglutinin (PHA)-stimulated PBMC, as well as B-LCL
(85, 123). Interestingly, killing of these targets involved antigenic
presentation by both classical class Ia and non-classical HLA-E
molecules indicating that multiple mechanisms might be involved
in killing of S. Typhi-infected cells (84, 85, 121).
Cell mediated immunity against S. Typhi mediated by CD4+
and CD8+ T-cells appears to depend on the nature of the stimu-
lant. CD4+ cells were more prone to respond to S. Typhi soluble
antigens while CD8+ cells were more likely to be activated by S.
Typhi-infected targets (84, 121, 138, 152). These results empha-
size the importance of selecting the appropriate type of stimulant
when designing experiments aimed at evaluating T-cell responses.
Another important issue related to the host’s response to S. Typhi
is the dichotomy between T-cell and humoral responses observed
in individual subjects. In the past, our group and others have tried
exhaustively, and failed, to observe a correlation on a volunteer
by volunteer basis between serum antibody titers to S. Typhi LPS
and/or S. Typhi flagella and CMI in individuals immunized with
various attenuated S. Typhi vaccine strains (42, 107, 121, 140).
These observations support the contention that the development
and dominance of humoral and/or CMI responses in individual
volunteers is likely multifactorial and influenced by individual host
factors (e.g., genetic makeup, gut microbiome composition).
On the basis of the expression of defined surface molecules,
T-cells can be simplistically subdivided into two main subsets:
naïve and memory T (TM) cells. Induction of strong and per-
sistent memory T-cell responses is one of the hallmarks of suc-
cessful vaccination (160, 171). Although TM can be divided into
a multitude of subsets, it is widely accepted that the main TM
subsets are central memory T-cells (TCM), and effector mem-
ory T-cells (TEM) (178, 179). TCM express surface molecules
for memory (e.g., CD45RO), as well as the chemokine recep-
tor CCR7 and CD62L (L-selectin) molecules, which allow effi-
cient homing to peripheral lymph nodes (178, 179). TEM also
express CD45RO, but down-regulate the expression of CCR7
and CD62L, which allows them to circulate and migrate to the
spleen and non-lymphoid tissues. In humans, some CD8+ TEM
lack the expression of CD45RO and express CD45RA, a molecule
present on naïve T-cells. This subset is termed TEMRA or “ter-
minal memory” cells (178, 179). Recently, we provided the first
demonstration of the induction and longevity (up to 2 years) of
TCM, TEM, and TEMRA multifunctional HLA-E restricted CD8+
TM cells after Ty21a immunization, suggesting that these cells
are important in long-term immunity to S. Typhi (82). In these
experiments, we showed that following Ty21a vaccination, mul-
tiple pro-inflammatory cytokines/chemokines (including IFN-γ)
are produced by CD8+ T-cells in response to stimulation with S.
Typhi-infected targets, and that these responses are multiphasic in
nature (82). We also observed a striking correlation among sub-
jects who showed strong CD8+ TCM subsets and produced IL-2
and IFN-γ at early times and the presence of long-term immune
responses (82). We speculated that this phenomenon might be
due to the fact that IL-2 and/or IFN-γ-secreting CD8+ TCM sub-
sets at early times after vaccination result in the development of a
larger pool of long-lived specific CD8+ TM cell subsets (e.g., CD8+
TCM, TEM and TEMRA subsets), which could lead to improved con-
trol against re-infection. Recently, these results were confirmed
and extended using multichromatic flow cytometry to measure
six cytokines simultaneously (IL-10, IL17A, IL-2, IFN-γ, TNF-α,
and MIP-1β) (92). In this work, our group demonstrated, for the
first time, the presence of IL-17A-producing CD8+ cells in Ty21a
vaccinees (92). These findings are of great significance since con-
sensus is emerging that multifunctional CD4+ and CD8+ T-cells
are important in determining the effectiveness of immunity to
either vaccination (180) or exposure to intracellular microorgan-
isms in humans, including HIV (181, 182) and Mycobacterium
tuberculosis (183, 184).
It is important to highlight that the balance between suppressive
and pro-inflammatory responses might be of critical importance
in the host’s ability to mount effective immune responses. For
example, experiments in mice have shown that the equilibrium
between suppressive Treg and pro-inflammatory Teff responses
influence the clearance or persistence of S. Typhimurium (185).
Treg are characterized by the expression of high levels of the
IL-2 receptor (CD25) and transcription factor Forkhead box P3
(FoxP3). Activated Treg may traffic to the sites of specific immune
responses and exert their regulatory functions via cell–cell inter-
actions [i.e., cytotoxic T lymphocyte antigen-4 (CTLA-4) compe-
tition for co-stimulatory molecules (CD80 and CD86) on APC],
consumption of IL-2, and production of anti-inflammatory fac-
tors [i.e., IL-10 and transforming growth factor (TGF)-β] (186).
Observations in humans, including IL-10 production by PBMC
from volunteers immunized with Ty21a and CVD909 in response
to S. Typhi flagellar antigen (52, 123) and IL-10 detection in
the sera of individuals during S. Paratyphi A infection (6) indi-
cate a potential role for Treg in establishing a balanced immune
response against S. Typhi and S. Paratyphi infections. Despite
these intriguing observations, the role of Treg following S. Typhi
or S. Paratyphi infection or immunization in humans remains
unknown.
Background T-cell responses and their possible role in controlling
Salmonella infection
A common finding when measuring T-cell immune responses in
humans vaccinated against enteric bacteria, such as S. Typhi, is the
presence of background S. Typhi-specific responses among indi-
viduals prior to immunization, even in the absence of travel to
endemic areas (81, 82, 84, 92, 121, 123, 136, 152). These back-
ground responses are characterized by the presence of specific
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immune responses against antigens from enteric bacteria in indi-
viduals with no history of immunization against, or infection
with, the enteric pathogen. Although this background is rather
variable, with higher levels observed in individuals in regions
with limited sanitation systems (unpublished observations), this
phenomenon has been observed in subjects across the World. A
prevailing hypothesis is that these background responses are due
to the presence of cross-reactive T-cells acquired during previous
infections by other enteric pathogens (81, 136, 151) or reacting
to the normal gut microbiota (187–190). Although it is difficult
to contest these possibilities, it is reasonable to hypothesize that
defined subset(s) of T-cells such as innate-like T-cells, including
TCRγδ T-cells, NK-T-cells, and MAIT, are responsible, at least in
part, for the observed background responses (151). For example,
TCRγδT-cells and NK-T-cells from healthy volunteers with serum
antibodies against non-typhoidal Salmonella have been reported
to produce higher amounts of IFN-γ as compared to conventional
CD4+ and CD8+ T-cells in response to stimulation with Salmo-
nella antigens (191). It is also known that MAIT cells play an
important physiological role in host bacterial defense and may also
be involved in inflammatory disorders, particularly at mucosal sur-
faces (192–194). Previous work has demonstrated that MAIT cells
may play a significant role in M. tuberculosis and HIV infections in
humans. Gold and colleagues have shown in humans that MAIT
cells are decreased in the blood of patients with active TB infec-
tion. Other reports have shown that the levels of MAIT cells were
severely reduced in circulation in patients with HIV-1 infection
(195, 196). Their decline was associated with the time of diag-
nosis (196) and may reflect diverse mechanisms including their
accumulation in tissues and activation and functional exhaustion
(195, 196). Of note, a recent study from our group has shown
that MAIT cells can be activated by B cells infected with various
bacteria (commensals and pathogens from the Enterobacteriaceae
family, including S. Typhi), but not by uninfected cells (151). These
responses were restricted by the non-classical MHC-related mol-
ecule 1 (MR1) and involved the endocytic pathway. Moreover, the
quality of these responses (i.e., cytokine profiles) were dependent
on bacterial load but not on the level of expression of MR1 or
bacterial antigen on B cell surface (151). Based on these studies,
it is reasonable to speculate that baseline responses by function-
ally active innate-like T-cells (e.g., TCRγδ T, NK-T, MAIT) and/or
those elicited early upon microbial stimulation by vaccination or
acute infection, might contribute to prevent S. Typhi infection.
These cell subsets may be responsible for controlling the infection
soon after exposure (subclinical infection), and contributing to
clear the infection without causing overt disease once the specific
adaptive immune responses are fully developed.
Dendritic cell cross-presentation and CD8+ T-cells
The mechanism(s) underlying S. Typhi regulation of the devel-
opment of specific T-cell responses in humans remains unclear.
Studies in mice have shown that DC can either directly (upon
uptake and processing of Salmonella) or indirectly (by bystander
mechanisms) elicit Salmonella-specific CD8+ T-cells (197). DC
are APC that have a strategic function in the initiation and mod-
ulation of the immune responses (198). In addition to presenting
exogenous antigens using the conventional MHC class II activation
pathway typically used by CD4+ T-cells, these cells have developed
an alternative pathway where exogenous antigens can be presented
through an MHC class I activation pathway to CD8+ T-cells (198).
This alternative pathway is called the cross-presentation pathway
(199). Although multiple APC are able to cross-present antigens,
DC are the most efficient in vivo (200). Therefore, the successful
generation of strong CD8+ T-cell responses to vaccine antigens
might be linked to the modulation of the DC cross-presentation.
Our group has provided the first direct demonstration in
humans that DC, through suicide cross-presentation, uptake S.
Typhi-infected human cells and release IFN-γ and IL-12p70, lead-
ing to the subsequent presentation of bacterial antigens and trig-
gering the induction of mostly CD3+CD8+CD45RA−CD62L−
TM cells (201). We observed that upon infection with live S.
Typhi, human DC produced high levels of the pro-inflammatory
cytokines IL-6, IL-8, and TNF-α but low levels of IL-12 p70
and IFN-γ (201). In contrast, DC co-cultured with S. Typhi-
infected cells produced high levels of IL-12 p70, IFN-γ, and
TNF-α (201). These interesting and novel findings are in agree-
ment with previous work showing that IL-12 and IFN-γ are
essential for resistance to Salmonella infection in mice (21,
202, 203), and that they are likely to also be important in
humans (38, 56). Thus, it is reasonable to speculate that cross-
presentation of vaccine antigens to CD8+ T-cells might be an
important mechanism of antigen presentation leading to the
generation of protective immune responses against S. Typhi
infection.
T-cell homing
Migration or “homing” is a multi-step process where the adhesion
of lymphocyte surface homing receptors to their counterparts,
addresins, on endothelial cells is the key step (204). As with B cells,
the selective homing of effector memory cells to the lamina propria
of the small intestine is driven, to a large extent, by the expression
of integrin α4β7 and CCR9 (205–209). For example, virtually all
T-cells in the small intestine express CCR9 (206). Another mole-
cule implicated in this process is integrin αEβ7 (CD103), which is
present in a subset of CCR9+ T-cells (210).
Generation of specific memory CD4+ and CD8+ T-cells with
gut homing potential following oral typhoid immunization has
been well described (81, 83, 152). Previous work has shown
that sorted integrin β7-expressing memory T-cells (CD45RA−
β7high cells) from volunteers immunized with S. Typhi vaccine
strain Ty21a when stimulated in vitro produced around 10-fold
more IFN-γ than the remaining populations (CD45RA− β7− or
CD45RA− β7intermediate) (81). Also, using cells from volunteers
immunized with the candidate S. Typhi vaccine strain CVD 909,
our group further characterized the gut homing potential and
induction of IFN-γ production in the central (TCM, CD45RO+
CD62L+) and effector (TEM, CD45RO+ CD62L−) memory T
populations (152). Interestingly, we observed that the homing
potential of CD4+ and CD8+ TM subsets were distinct. Although
both CD4+ TEM and TCM populations produced IFN-γ, CD4+
TCM cells were predominantly integrin α4β7+ while CD4+ TEM
were found to include both integrin α4β7+ and integrin α4β7−
cells. In contrast, IFN-γ-producing CD8+ cells were predom-
inantly classical TEM and CD45RA+ TEM (TEMRA; CD45RO−
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CD62L−) subsets. Interestingly, while CD8+ TEM included both
integrin α4β7+ and integrin α4β7− cells, CD8+ TEMRA were pre-
dominantly integrin α4β7+ (152). By using PBMC from healthy
adults immunized with the Ty21a vaccine, we have also reported
that S. Typhi-specific CD8+ T-cells are able to co-express high
levels of integrin α4β7, intermediate levels of CCR9 and low levels
of CD103 (83). Furthermore, we showed that these specific mem-
ory CD8+ T-cells with gut homing potential bear multiple TCR
Vβ specificities (e.g., Vβ2, 3, 8, 14, and 17) (83). Of note, cells
used in this study were collected 5–40 months after oral immu-
nization. Thus, S. Typhi-specific CD8+ TEM cells with gut homing
potential might persist in circulation over long periods of time.
However, because the study used cells isolated exclusively from
peripheral blood, we have to consider the possibility that these
observations might not reflect the full spectrum of TCR Vβ usage
by S. Typhi-specific CD8+ T-cells in the gut microenvironment
in vivo. Based on these findings regarding the homing potential of
S. Typhi-specific cells, it is reasonable to speculate that the observed
multiphasic kinetics of the T-cell responses described above might
represent decreases in circulating S. Typhi-specific T-cells as they
home to the gut and other lymphoid tissues, as well as increases
due to the release into the circulation of new waves of specific cells
generated in lymphoid organs.
MICROBIOTA, CO-INFECTIONS, AND THE HOST IMMUNE
RESPONSE FOLLOWING IMMUNIZATION WITH ORAL
ATTENUATED TYPHOID AND OTHER ENTERIC VACCINES
There is growing evidence from clinical studies indicating that
the gut microbiota has a profound impact in modulating human
immune responses in health and disease, including a significant
role in influencing vaccine efficacy (190, 211–213). For exam-
ple, in a study evaluating the oral attenuated V. cholerae O1
vaccine CVD 103-HgR, Lagos and colleagues demonstrated that
excessive bacterial growth (“tropical enteropathy”) in the small
intestine of children in less developed countries might contribute
to the low-antibody response to the vaccine (214). In this study,
an inverse association was found between bacterial over growth
and seroconversion as determined by vibriocidal titers. Reduced
vaccine efficacy and immunogenicity in developing countries
when compared with North Americans also has been reported
with other vaccines, including oral polio and rotavirus (137, 213,
215). Helminth infections have also been demonstrated to impact
vaccine immunogenicity and, for example, anti-helminthic ther-
apy prior to immunization was shown to improve the immune
response to the CVD 103-HgR cholera vaccine (216). Regard-
ing S. Typhi, recent evidence showed that the induction of S.
Typhi-specific IgG LPS antibodies following immunization was
significantly higher among CVD 908-htrA vaccines infected with
Helicobacter pylori than in uninfected subjects. These results are
likely the consequence of gastric acid hyposecretion due to H.
pylori infection which facilitated the passage of CVD 908-htrA
through the stomach (217). These observations are supported
by reports indicating that the risk of developing typhoid fever is
higher in H. pylori-infected individuals in underdeveloped coun-
tries (218), suggesting that the success of the Ty21a typhoid vaccine
in endemic regions might be the result, at least in part, of the high
prevalence of H. pylori infection accompanied by hypochlorhydria
(217, 219). Additionally, evidence in animal models suggests that
modulation of the gut microbiota (e.g., with antibiotics, prebiotics,
and probiotics) can enhance vaccine efficacy (220, 221).
We recently initiated studies to directly investigate the inter-
actions between the microbiome and vaccination with attenuated
oral vaccines. We observed that, although Ty21a is a live-attenuated
S. Typhi vaccine delivered via the oral route, there was no dis-
ruption in the composition, diversity, or stability of the fecal
microbiota in healthy adult volunteers who received this vaccine
(172). However, categorical analysis based on multiphasic CMI
responses versus late CMI responses identified a subset of bacter-
ial operational taxonomic units (OTUs) differentiating individuals
capable of mounting distinct immunological responses. Gener-
ally, individuals who exhibited a multiphasic CMI response to
vaccination harbored greater community richness and diversity
compared to individuals with only a late CMI response to Ty21a.
No differences were identified in community richness or diversity
among volunteers characterized as responders or non-responders
based on seroconversion (S. Typhi LPS). Although the number
of volunteers analyzed was small, this study provides additional
information supporting the potential influence of the gut micro-
biota on the immune response elicited by oral immunization,
and perhaps, in protection. Additional studies involving larger
numbers of volunteers and a multiplicity of vaccines adminis-
tered via the oral route are necessary to extend our understanding
of the complex role of the gut microbiota in modulating host
immunity and vaccination in humans, and its possible role in
vaccine efficacy.
CROSS-REACTIVE IMMUNE RESPONSES AMONG S. Typhi, S.
Paratyphi A, AND S. Paratyphi B
As discussed above, limited information is available regarding host
immune responses to S. Paratyphi A and S. Paratyphi B in humans.
In fact, most of the immune responses believed to be elicited by S.
Paratyphi A have been inferred from S. Typhi studies. Interestingly,
field trials of Ty21a have shown modest cross-protection against S.
Paratyphi B (3), suggesting that cross-reactive immune responses
might be responsible. The presence of cross-reactive responses
were first reported in the 1980s by Tagliabue et al. who reported
the induction of IgA antibodies following oral immunization with
Ty21a, which mediate T-cell-dependent ADCC against S. Typhi,
S. Paratyphi A, and S. Paratyphi B, but not against S. Paratyphi
C (87). We have recently identified cross-reactive immunological
responses against S. Paratyphi A and S. Paratyphi B in subjects
orally immunized with Ty21a (91). IgA ASC that recognized LPS
from S. Paratyphi A and S. Paratyphi B were observed, but at a
lower magnitude than responses against S. Typhi LPS (91). These
cross-reactive anti-LPS CD19+ CD27+ IgG and IgA ASC displayed
the same homing pattern (i.e., a dominant integrinα4β7+CD62L−
subset and a significant proportion of integrin α4β7+ CD62L+
cells) as S. Typhi-specific ASC. We also reported the induction of
antibodies and BM to S. Typhi LPS and OMP antigens, which cross-
react with S. Paratyphi A and S. Paratyphi B. However, IgA BM
reactive to S. Typhi was of higher magnitude than those against S.
Paratyphi A and S. Paratyphi B. In contrast, BM to outer membrane
proteins (OMP) from S. Paratyphi B were similar to those observed
for S. Typhi-OMP,but higher than those for S. Paratyphi A OMP. In
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a subsequent study, we reported in Ty21a and CVD 909 vaccines
the presence of cross-reactive serum antibodies able to mediate
opsonophagocytosis of S. Paratyphi A and S. Paratyphi B, albeit
at lower levels than those against S. Typhi (90, 91). Similar obser-
vations regarding cross-reactive ASC responses among S. Typhi
and S. Paratyphi serovars A, B, and C were recently reported in
Ty21a vaccinees and patients with enteric fevers (222). These cross-
reactive responses are likely the result of the immunity elicited
by O:12, the trisaccharide (mannose–rhamnose–galactose) repeat-
ing unit that comprises the LPS backbone, which is common to
S. Typhi, S. Paratyphi A, and S. Paratyphi B. Of note, a recent
study showed that, although S. Paratyphi A and S. Paratyphi B
do not possess the Vi antigen, cross-reactive ASC were identified
in recipients of the Vi polysaccharide vaccine (223). The authors
concluded that this low level of cross-reactivity is likely attrib-
utable to S. Typhi-LPS contamination of the Vi polysaccharide
vaccine. Similar observations were reported by others (89, 139). Of
note, although to our knowledge there are no reports document-
ing cross-protection against non-typhoidal Salmonella in Ty21a
or Vi vaccinees, these typhoid immunizations elicit cross-reactive
ASC against non-typhoidal Salmonella, including S. Typhimurium
and Enteriditis that share either O:9, O:12, or both antigens with
S. Typhi (224, 225). In spite of these studies, the precise immune
mechanism(s) of the cross-protection observed against S. Paraty-
phi B in Ty21a vaccinees in field trials remains unclear. However, it
is tempting to speculate that CMI responses might play a key role
in cross-protection. Further studies assessing the basis for these
cross-reactive responses, as well as whether immunization with
novel attenuated S. Paratyphi A vaccines, or wild-type S. Paratyphi
A infection, results in cross-reactive humoral and CMI responses
with S. Typhi and S. Paratyphi B will provide critical information
to advance the development of broad-spectrum vaccines to protect
against enteric fevers.
“OMICS” STUDIES
Recent advances in microarray and proteomics technologies have
allowed for detection of immunogenic S. Typhi antigens (226,
227). Both immunoaffinity proteomics-based technology and
protein microarrays have been utilized to identify key antigens
that may be suitable for vaccine development and diagnostics
(226, 227). Furthermore, transcriptional profiling in peripheral
blood of patients infected with S. Typhi identified a distinct
and reproducible signature that changed during treatment and
convalescence (228). Additionally, studies performed in mice and
humans have also identified immune signatures common to
murine and human systemic salmonellosis (229). Although very
few manuscripts have reported the use of these state-of-the-art
approaches, these comprehensive analyses of the transcriptional
and proteomic profiles provide a foundation for more directed
analyses that may have a direct impact on the development of
novel vaccines and diagnostics in coming years.
CONCLUDING REMARKS
Despite decades of effort, the mechanisms of protective immu-
nity in natural infection and vaccination remain largely unde-
fined and many questions remain (Box 1). The vast majority of
the information currently available using modern immunologi-
cal techniques has been obtained using specimens from subjects
immunized with attenuated typhoid vaccines. Old challenge stud-
ies lacked the appropriate tools to monitor immune cells (e.g., B-
and T-cells) and in general, have been limited to measurements
of serum antibody titers and, in some cases, the use of inadequate
CMI methodology available at that time. The “Renaissance” of
challenge studies with wild-type S. Typhi, such as those being per-
formed in Oxford, is at hand and novel technologies to analyze
in unprecedented depth the host immune responses have recently
become available. One of these technologies is mass cytometry,
also known as Cytometry by Time Of Flight (CyTOF), capable of
resolving more than 35 measurements per cells using rare metal-
conjugated monoclonal antibodies with minimal signal overlap
(230–232); a problem that severely limits the number of parame-
ters, which can be evaluated by conventional flow cytometry. This
novel technology will enable the simultaneous measurement of the
phenotype and function of multiple immune cell types by simul-
taneously monitoring the cross-talk between traditional players
(e.g., B- and T-cells), and new potential players (e.g., innate-like
T-cells, including TCRγδ T-cells, NK-T-cells, and MAIT cells, as
well as Treg cells) and the possible mechanisms leading to protec-
tion against infection. In fact, it is likely that it is the balance (i.e.,
homeostasis) between effector and regulatory responses that holds
the key to understanding protective immunity. Mass cytometry, in
conjunction with traditional immunological assays and state-of-
the-art genomics, transcriptomics, proteomics, and metabolomics
approaches and the availability of human challenge models pro-
vide, for the first time, the necessary tools to uncover the mech-
anisms underlying protective immunity, both systemically and
Box 1 Key remaining questions.
• What are the relative contributions of humoral and cellular responses to protection?
• What are the precise roles of effector and memory B and T-cells, as well as innate immune cells in protection?
• How can an appropriate balance between pro-inflammatory and regulatory responses be achieved, resulting in protection without causing
excessive inflammation?
• What are the mechanisms of enduring protection against S. Typhi, S. Paratyphi A, and S. Paratyphi B and how can long-lasting responses
be preferentially induced?
• What are the characteristics of protective local gut immune responses?
• What are the differences and similarities between local and systemic immune responses?
• What is the role of the gut microbiota in modulating immune responses against enteric fevers?
• Can cross-reactive immune responses between S. Typhi, S. Paratyphi A, and S. Paratyphi B be exploited to develop broad-spectrum
vaccines against enteric fevers?
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in the gut microenvironment. This information will be invalu-
able in accelerating the development of novel vaccine strategies
to prevent enteric fevers. In addition, the expected explosion of
knowledge regarding the gut microbiome and its role in modulat-
ing immunity to oral vaccines is also likely to provide significant
insights in coming years in understanding the observed differences
in immunogenicity between vaccine responses in developed and
developing countries.
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